Global Pharmaceutical Regulation: Comparative Frameworks and Operations
Top Cited Papers
Open Access
Abstract
Pharmaceutical regulation plays a central role in protecting public health by governing clinical trials, market authorization, and post-marketing safety monitoring throughout the medicine life cycle. While substantial literature describes established systems, particularly the United States Food and Drug Administration (FDA), Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), and the European medicines regulatory network coordinated by the European Medicines Agency (EMA) together with national competent authorities, comparative analyses that integrate both mature authorities, emerging regulators and transnational harmonization networks remain limited. This narrative review draws on primary regulator/network documentation and targeted peer-reviewed literature to compare core regulatory functions across jurisdictions, including approval pathways and evidentiary expectations, inspection and good manufacturing practice (GMP) oversight, transparency practices, and pharmacovigilance and risk-management approaches. Across regions, we observe increasing convergence in scientific expectations through initiatives such as the International Council for Harmonisation (ICH) and reliance and work-sharing models, alongside persistent differences in legal mandates, resourcing, timelines, and data requirements. These differences are most consequential for complex products (e.g., advanced therapies) and in crisis settings, where emergency or conditional authorizations amplify the need for strong lifecycle monitoring, real-world evidence governance, and cross-border communication. We conclude by outlining opportunities to strengthen regulatory resilience and equity through fit-for-purpose harmonization, investment in enabling infrastructure, and future work on interoperable data systems, signal detection, and coordinated post-marketing evaluation.Keywords
All Related Versions
This publication has 37 references indexed in Scilit:
- History, status, and politicization of the FDAResearch in Social and Administrative Pharmacy, 2022
- Translating the Principle of Beneficence into Ethical Participatory Development Research PracticeJournal of International Development, 2021
- Using digital technologies in clinical trials: Current and future applicationsContemporary Clinical Trials, 2020
- Ethical considerations of gene editing and genetic selectionJournal of General and Family Medicine, 2020
- FDA Approval and Regulation of Pharmaceuticals, 1983-2018JAMA, 2020
- ES10.05 Brazilian Health Regulatory Agency - Agência Nacional de Vigilância SanitáriaJournal of Thoracic Oncology, 2019
- Cell, tissue and gene products with marketing authorization in 2018 worldwideCytotherapy, 2018
- Pharmaceutical Policy in Argentina2017
- Overcoming Challenges Facing Advanced Therapies in the EU MarketCell Stem Cell, 2016
- Drugs and DevicesJACC: Basic To Translational Science, 2016